Refine by
Cancer Diagnosis Articles & Analysis: Older
201 news found
The International Agency for Research on Cancer reports that as recently as 2020, there were over 13,000 new cases of cancer in Puerto Rico. Tragically, there were also more than 5,500 deaths due to cancer in Puerto Rico that year alone. The American Association for Cancer Research has reported that more than 40% of all diagnosed cancers in the U.S. can be attributed to preventable causes. ...
Around half of all men say lack of sexual function is a significant problem to them after prostate cancer intervention, highlighted in an international survey from 32 countries and over 5000 men by the Europa-Uomo group1. Real world evidence is important to understand what is happening to patients in healthcare2, so AngioDynamics welcomed the news last week that the UK’s National Institute ...
Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET CT at baseline Fifth major clinical trial for androgen receptor inhibitor (ARi) darolutamide, covering prostate cancer from early to metastatic stage Bayer further expands ...
ByBayer AG
Nubeqa now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer Additional indication based on data from the pivotal Phase III ARASENS trial The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor inhibitor (ARi) Nubeqa™ (darolutamide) in ...
ByBayer AG
“This approval is supported by robust data from the ARASENS clinical trial, which demonstrate the benefits of darolutamide plus ADT in combination with docetaxel in extending survival, delaying disease progression and maintaining quality of life for patients with metastatic hormone-sensitive prostate cancer.” Prostate cancer is the most commonly ...
ByBayer AG
Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer New approval based on data from the pivotal Phase III ARASENS trial The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the oral androgen receptor inhibitor (ARi) darolutamide plus ADT in combination with docetaxel in the ...
ByBayer AG
Ali Tinazli's post at the Forbes magazine about "How Technology, Early Diagnoses Can Help Turn The Tide On Prostate Cancer Prognosis" There has never been more hope or promise in the global effort to eradicate cancer. ...
In 2020, an estimated 1.4 million men were diagnosed with prostate cancer, and about 375,000 died from the disease worldwide.80F[i] At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. ...
ByBayer AG
While cancer mortality has gradually declined over the past several decades in Puerto Rico, there are still more than 10,000 new cases of cancer and over 5,000 deaths each year on the islands. Nationwide, the National Cancer Institute estimates there were over 1,918,000 new cases of cancer diagnosed in 2022 and more than 609,000 people died from cancer that year alone. There are over 100 types ...
ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers. ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat. ORSERDU is the first endocrine innovation in more than 20 years, specifically addressing ESR1 mutations, a major unmet need. The Menarini Group (“Menarini”), a ...
Prostate cancer is the most commonly diagnosed cancer in men in almost all northern and western European countries.1 Only 30% of men with mHSPC will survive five years or more after diagnosis.2 Most men with mHSPC eventually progress to metastatic castration-resistant prostate cancer (mCRPC), a condition with limited long-term ...
ByBayer AG
In 2019, 4D Path successfully closed a ~USD 4.4M funding round with the Seed Three Convertible Preferred Stock offering, bringing their total funds raised to $6.4M. The latest round will support legal and consulting costs as well as continued expansion of its research, team, infrastructure, data acquisition and business development. 4D Path’s patented precision oncology ...
xCures, Inc. is proud to announce their partnership with RenovoRx, a clinical-stage biopharmaceutical company that focuses on fighting cancer through localized treatment of difficult-to-treat tumors, such as pancreatic adenocarcinoma. Through this collaboration, xCures will help eligible pancreatic cancer patients access a Phase III clinical study entitled, Targeted Intra-arterial Gemcitabine vs. ...
ByxCures
Cirdan are delighted to announce that together with Queen’s University Belfast and our KTP Associate and Senior AI Engineer, Jonathan Armstrong, we have been selected as the winners of the Best KTP project by Innovate UK. Innovate UK’s Best Knowledge Transfer Partnership award honours the KTP which has brought the greatest benefits to all three participants, exceeding the expectations ...
“This day marks a paradigm shift in medical isotope supply wherein the international medical community can now depend on scalable, reliable, Canadian, power-reactor produced isotopes for their cancer treatments.” The IPS will leverage Bruce Power’s continual operations 24 hours a day, seven days a week to provide a consistent and scalable supply of life-saving ...
As a result, NIR quantum dots have expanded the application of quantum dots in physical analytical chemistry and become a powerful tool for medical diagnosis and physical analysis. As a new type of fluorescent marker, NIR quantum dots have excellent biological imaging properties, such as high fluorescence intensity, good fluorescence stability, sufficient electron density, and ...
For many families, November signals the start of the holiday season. It is a special time to gather with loved ones and check-in to make sure everyone is happy and healthy. November is also lung cancer awareness month. VisionGate wants to help you, your family and loved ones learn more about who is at risk, the impact, and the types of lung cancer. Because keeping yourself informed ...
At SeqOne, Michael will lead scientific research and the development of new genomic analysis solutions to improve the clinical interpretation and diagnosis of cancer and hereditary diseases. Michael Blum has co-authored over 50 scientific publications, many of which are the fruit of international collaborations in the fields of population genomics and genomic ...
Two powerhouse researchers in prostate cancer will change the way we treat the disease, thanks to funding from legendary volunteer fundraisers, the Bird Dogs and the Alberta Cancer Foundation. ...
Rarecells, Inc., an innovative Liquid Biopsy company developing non-invasive tests for early cancer diagnosis, announced today the closing of a $5 Million tranche, bringing its total Series A funding to $13 Million. ...